Iżrael - Ingliż - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril - entresto is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entresto has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Iżrael - Ingliż - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Iżrael - Ingliż - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Iżrael - Ingliż - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entresto is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entresto has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Iżrael - Ingliż - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Iżrael - Ingliż - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Iżrael - Ingliż - Ministry of Health

novartis israel ltd - ondansetron as hydrochloride dihydrate - tablets - ondansetron as hydrochloride dihydrate 8 mg - ondansetron - ondansetron - adults:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy.

Iżrael - Ingliż - Ministry of Health

novartis israel ltd - ondansetron as hydrochloride dihydrate - tablets - ondansetron as hydrochloride dihydrate 4 mg - ondansetron - ondansetron - adults:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy.

Iżrael - Ingliż - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - film coated tablets - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting .• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

Iżrael - Ingliż - Ministry of Health

novartis israel ltd - tisagenlecleucel - dispersion for infusion - tisagenlecleucel - kymriah is indicated for the treatment of: - paediatric and young adult patients up to and including 25 years of age with cd19+ b-cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post-transplant or in second or later relapse. - adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy. limitation of use: kymriah is not indicated for treatment of patients with primary or secondary central nervous system lymphoma- adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy